Business Wire

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

Share

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.

“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”

About Project Integrum

Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Biocytogen’s Contacts:
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KartRider: Drift Races Into Its Inaugural Season With Console Cross-play Date Reveal31.1.2023 19:01:00 CET | Press release

KartRider: Drift, Nexon’s completely free-to-play kart racing title, announced today its Season One date when consoles will join the online racing mix. Current Preseason PC and mobile racers on Steam, Nexon Launcher, Android, and iOS, will soon be able to compete head-to-head against Xbox and PlayStation players from all over the globe in thrilling, drift-fueled racing. Full cross-platform, cross-play will be available when Season One “New World” arrives on March 8. Season One also brings with it exciting new content – brand new tracks and race modes, a season-long theme, daily player rewards and events, plus many other improvements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005459/en/ Nexon's "KartRider: Drift" Announces March 8 Season One Arrival Date With New Gameplay Trailer. (Graphic: Business Wire) KartRider: Drift isn’t as simple as it may seem! The easy-to-learn, hard-to-master game offers distinct game mo

PPG achieves ISO 14001 certification of environmental management system31.1.2023 16:00:00 CET | Press release

PPG (NYSE: PPG) today announced that it has achieved International Organization for Standardization (ISO) 14001 certification for an environmental management system (EMS) at its Shannon, Ireland, operations. The company manufactures highly efficient, high-performing organic light-emitting diode (OLED) materials at the Universal Display Corporation (UDC) (Nasdaq: OLED) site. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005097/en/ PPG produces phosphorescent organic light-emitting diode (OLED) materials and technologies for Universal Display Corporation (UDC) that are up to four times more energy-efficient than conventional fluorescent OLED materials. UDC’s proprietary UniversalPHOLED® technology enhances the performance of consumer displays and lighting products by providing power savings that enable longer battery life in portable electronics and less energy consumption in larger display and lighting products. (Photo

Interactive Brokers Unveils New Feature to Help Clients Achieve Even Better Price Execution on US Options Trades31.1.2023 16:00:00 CET | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of its new IBUSOPT order destination. With the dramatic increase in retail options trading, Interactive Brokers has launched this new order destination to help its retail and institutional clients achieve better price execution on their options trades. IBUSOPT, a new order destination for US equity and index options, is designed to offer clients the opportunity to interact with IBKR SmartRoutedTM order flow and have their orders filled in between the National Best Bid/Offer (NBBO). The IBUSOPT destination helps traders execute options trades more efficiently and effectively and helps achieve better executions by providing traders with more control over their trades by supporting different order types. IBUSOPT orders will wait for an offsetting order from another IB customer and will not be shown to the market. The IBUSOPT-Pegged-to-Midpoint order type allows clients to peg their order

Hyosung America Launches New Brand Identity – Hyosung Innovue31.1.2023 16:00:00 CET | Press release

Hyosung America today announced “Hyosung Innovue,” a new brand identity. The change is the culmination of a year-long effort to reframe the company’s story of value as a human experience maker. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005393/en/ Hyosung Innovue -- improving life's day-to-day interactions for everyone. (Graphic: Business Wire) “Our company has a long history of harnessing its unique combination of a manufacturer’s soul with an innovator’s mindset to build a platform of ATM and cash-management solutions,” said Sanghwan Kweon, CEO of Hyosung America. “We are opening the aperture to extend our value creation deeper into financial services and retail while we bring our platform of integrated solutions to new verticals including hospitality and travel.” “It’s all about improving life’s day-to-day interactions for everyone,” said Brad Nolan, CMO of Hyosung America. “We elevate experience by bridging the

Botify Launches Botify Activation to Accelerate Speed to Market and Content Discoverability for the World’s Most Ambitious Brands31.1.2023 15:00:00 CET | Press release

Botify, a leading performance marketing platform for organic search, today announced the launch of Botify Activation to empower organizations to regain control of how search engines and consumers find products and services organically online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005318/en/ A key suite within the Botify Platform, which already includes Botify Analytics and Botify Intelligence, Botify Activation connects insights about a website’s performance with making brands more discoverable online. By enabling scalable, automated site improvements and content discoverability, Botify Activation provides brands with the ability to expedite how search engines discover and interpret website pages—improving speed to market while also boosting efficiency across teams. Specifically, Botify Activation is comprised of the following solutions: SpeedWorkers: Serves fully-rendered pages to search engines, ensuring mor